Parameter
| Biomarker | Gut microbiota (specific flora: Bifidobacterium, Lactobacilli, Enterobacteriaceae, etc.) | Full name | Gut microbiota (specific flora: Bifidobacterium, Lactobacilli, Enterobacteriaceae, etc.) | Molecular Type | Microbial communities |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Metabolic regulation, immune regulation, gut-liver axis regulation | ||
| Disease | Viral Hepatitis | Disease Subtypes | / | ||
| Organ | Liver/Gut | Test Sample / Technology Platform | Stool, Serum | ||
| Pathobiological Mechanisms | Through metabolites (short-chain fatty acids, LPS) to affect liver immune and inflammatory response; The imbalance of microbiota (the increase of harmful bacteria and the decrease of beneficial bacteria) destroys the intestinal barrier and promotes the occurrence of liver fibrosis and liver cancer | ||||
| Clinical Availability Status | Clinical research phase | ||||
| Notes and Dynamics | As a non-invasive marker, it can reflect the function of gut-liver axis, and its modulation therapy (probiotics and prebiotics) has shown potential in adjuvant treatment. However, the composition of the microbiota is highly heterogeneous, and standardized detection and analysis methods are needed | ||||